Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization – – Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis – NEW YORK, May 19, 2026 /PRNewswire/ --  Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" W. Bonney, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective May 16, 2026.